The opiomelanotropinergic neuronal and endocrine systems

Long-term haloperidol treatment elevates beta-endorphin levels in the intermediate pituitary but not in rat brain

Long-term treatment of rats with haloperidol, a dopamine receptor antagonist, produced a dose-dependent increase in immunoreactive beta-endorphin (i beta-END) concentrations in the neurointermediate lobe of the pituitary (NIL). In contrast, chronic haloperidol treatment had no significant effect on i beta-END levels in the hypothalamus, the midbrain or in discrete, microdissected brain nuclei even when administered at a dose (5 mg/kg) ten-fold higher than that which elevated i beta-END levels in the NIL. Chronic treatment with bromocriptine, a dopamine receptor agonist, had the opposite effect on the NIL, lowering i beta-END levels to approximately one-third of control values, but it did not affect hypothalamic i beta-END concentrations. These data are consistent with prior evidence that the synthesis of beta-END by IL melanotrophs is reciprocally modulated by dopaminergic ligands. The results indicate, however, that beta-END-releasing neurons are not similarly regulated.

The effect of reserpine on the pars intermedia of the rat pituitary. An electron-microscopic, fluorescence-histochemical and immunohistochemical study

Reserpine has a stimulatory effect on the pars intermedia of the rat pituitary, probably mediated by its action on regulatory catecholaminergic nerves. The effect of single intraperitoneal injections of 0.1-20 mg/kg b.w. of reserpine was studied in adult male rats. Reserpine at a dose of 2 mg/kg b.w. induced degranulation, orientation of the secretory granules along the cell membrane and loss of formaldehyde-chloral-induced fluorescence, accompanied by an activation of the granular endoplasmic reticulum and the Golgi apparatus. With higher doses progressive degranulation and loss of fluorescence were observed. The effect was, however, heterogeneous, and with all doses cells displaying normal ultrastructure and normal fluorescence were regularly present. To study the release of granular products (containing a different components of the pro-opiomelanocortin chain) from individual cells, formaldehyde-chloral induced fluorescence and alpha-MSH- and beta-endorphin immunoreactivies were demonstrated in consecutive sections from pituitaries of rats given 8 mg/kg body weight of reserpine 24 h before sacrifice. The results indicate coordinated release of these granular products at the cellular level after reserpine treatment.

High-performance liquid chromatographic analysis of in vitro central neuropeptide processing

Reversed-phase high-performance liquid chromatography (HPLC) was used to study and characterize the in vitro proteolytic processing of beta-endorphin by twice-washed membrane homogenates. A high-resolution method, capable of separating over 30 different human beta-endorphin-related fragments in a single analysis, was used to study the time course of production of specific, biologically active endorphin fragments by membrane-associated proteases. The results demonstrate that frozen (-37 degrees C), postmortem human and rat brains are viable for processing studies and that metabolism proceeds similarly to that in fresh brain homogenates or slices. Significant differences were noted in the formation rates of putative neuroleptic peptides between sex- and age-matched postmortem brain tissues from controls versus postmortem brain tissues from neuropsychiatric patients or drug-treated animals. These data suggest that using HPLC to characterize neuropeptide processing in human or rat membrane-associated enzyme homogenates is both descriptive and quantitative and offers insight into the central regulation of neuropeptide metabolism.

CRF-containing neurons of the rat hypothalamus

The immunoreactive CRF-neurons of the rat hypothalamus have been examined immunohistochemically employing anti-rat CRF serum. These neurons are confined to the paraventricular nucleus, dorsomedial-lateral hypothalamic area, and suprachiasmatic nucleus, and are, respectively, also immunoreactive to anti-Met-enk, -alpha-MSH, and -VIP sera. Intraventricular administration of colchicine (50 micrograms/5 microliters/rat) induces a dramatic enhancement of the immunostainability of the cell somata, and also accelerates the development of immunoreactivity of other stored peptides, especially in the paraventricular nucleus. The CRF-neurons respond to adrenalectomy by showing increased immunoreactivity and an increase in the number of cell bodies; in the dorsomedial-lateral area and suprachiasmatic nucleus, there is also an enhanced immunoreactivity for alpha-MSH and VIP, respectively. CRF-cells in the paraventricular nucleus become markedly hypertrophied, but do not show any enhanced immunoreactivity for Met-enk. Since the axons of the paraventricular neurons run to the median eminence, it is probable that they are involved with the endocrine control of hypophysial ACTH release. It is concluded that the CRF-containing neurons in rat hypothalamus consist of three types which are functionally and morphologically different.

The alpha-adrenergic receptor: radiohistochemical analysis of functional characteristics and biochemical differences

The partial agonist [3H]para-aminoclonidine was used to label alpha 2-adrenergic binding sites in intact sections of the rat central nervous system using in vitro labeling receptor autoradiographic techniques. The distribution of alpha 2-agonist binding sites closely parallels the reported distribution of noradrenergic and adrenergic cell groups and their terminal fields, particularly the projections of the medullary catecholamine neurons. This distribution of alpha 2 binding sites confirms physiological studies which indicate that the anti-hypertensive actions of alpha 2-agonist compounds are mediated centrally in medullary and spinal centers involved in the control of parasympathetic and sympathetic outflow. Further, the high concentrations of alpha 2 binding sites in pontine and limbic areas such as the locus coeruleus, parabrachial nucleus, dorsal raphe, hypothalamus, amygdala, bed nucleus of the stria terminalis, septum and entorhinal cortex offer an anatomical basis for understanding the anxiolytic and antidepressant actions of drugs like clonidine. The antagonists [3H]prazosin and [3H]WB4101 were used to study the distribution of alpha 1-adrenergic binding sites in the rat forebrain and biochemical studies were performed to analyze the marked differences that were initially seen in the distribution of [3H]prazosin and [3H]WB4101 binding sites. Several pieces of evidence derived from both biochemical and autoradiographic studies suggest that [3H]prazosin and [3H]WB4101 act at distinctly different binding sites. However, both sites may represent components of an alpha 1-adrenergic receptor-effector complex since a high degree of overlap was seen in the binding site distribution of these two ligands and since kinetic interactions could be demonstrated in at least one region of the brain, the hippocampus. Differences noted in the relative displacements of [3H]prazosin and [3H]WB4101 binding in various forebrain regions could reflect differences in the coupling efficiency of the [3H]prazosin and [3H]WB4101 component of the hypothesized complex. Further, in some regions, [3H]WB4101 labeled a binding site that is different from the alpha 1-receptor. Thus, [3H]prazosin and [3H]WB4101 binding sites seen in forebrain regions such as lamina V of the cortex, thalamic nuclei and dorsal raphe probably represent alpha 1-adrenergic receptors and confirm electrophysiological and biochemical studies which demonstrate that adrenergic transmission in these regions can be mediated through an alpha 1-receptor.

Stimulation of aggression in male mice by alpha-MSH and its relation to light phase and to saline intake effects

The resident/intruder test was used to examine the social approach and aggressive behaviour of male albino mice. Digging, self-grooming and rearing were also recorded, as was the post-test response to hot-plate exposure. The resident mice were given either a single acute injection of MSH (MSH); 0.9% NaCl to drink (for 48 h prior to testing; SAL); a combination of both treatments (MSH + SAL) or an injection of 0.9% physiological saline (control group; CON). Testing was carried out at the midpoints of the light and dark phases of the 12:12 light cycle. Data on plasma ion levels and hypothalamic cAMP levels were collected after the hot-plate test. MSH stimulated fighting both in the light and dark, and SAL in the light. MSH + SAL reversed the effects of the single treatments in that fighting declined below CON levels in both light and dark. Social contact and other behaviours were much less affected by treatments. Pain responding and plasma ion levels were not changed. Effects on cAMP were largely inconclusive, but intruders had significantly lower levels than the aggressive resident animals.

Suppression of basal and stress-induced prolactin release and stimulation of luteinizing hormone secretion by alpha-melanocyte-stimulating hormone

alpha-MSH and beta-endorphin, both synthesized from a common precursor, have opposite behavioral actions. In order to determine if these peptides have opposite effects on pituitary function, basal LH secretion and basal and stress-induced prolactin release were studied in adult male rats after intraventricular injection of alpha-MSH. Each rat also received intraventricular saline in order to serve as its own control. 18 micrograms alpha-MSH stimulated plasma LH from 16.5 +/- 2.5 (SEM) ng/ml to a peak of 27.2 +/- 4.0 and 26.0 +/- 4.9 ng/ml at 5 and 10 min, and suppressed prolactin from 3.5 +/- 0.7 ng/ml to 1.3 +/- 0.1 and 1.2 +/- 0.1 ng/ml at 15 and 30 min. Intraventricular alpha-MSH also significantly blunted the prolactin rise associated with the stress of swimming. 10 and 20 min after the onset of swimming, prolactin levels in rats pretreated with alpha-MSH were significantly diminished: 7.4 +/- 1.5 and 6.5 +/- 2.0 ng/ml vs 23.8 +/- 3.6 and 15.2 +/- 2.8 after normal saline. Similarly, des-acetyl alpha-MSH which is the predominant form of alpha-MSH in the hypothalamus, diminished the stress-induced prolactin rise from 18.4 +/- 5.3 and 11.2 +/- 3.4 ng/ml at 10 and 20 min to 10.0 +/- 2.4 and 5.5 +/- 1.6 ng/ml. We conclude that centrally administered alpha-MSH stimulates LH and suppresses basal and stress-induced prolactin release in male rats. These actions are opposite to those previously shown for beta-endorphin and suggest that alpha-MSH may antagonize the effects of beta-endorphin on pituitary function.

Topographical distribution of pro-opiomelanocortin-derived peptides (ACTH/beta-END/alpha-MSH) in the rat median eminence

The detailed distribution of adrenocorticotropin (ACTH), beta-endorphin (beta-END) and alpha-melanotropin (alpha-MSH) immunoreactivity was examined in the rat median eminence (ME) and pituitary stalk using light microscopic immunocytochemistry and radioimmunoassay (RIA). Nerve fibers and varicosities immunoreactive for ACTH/beta-END/alpha-MSH had identical distributions in the ME suggesting that they are part of the same arcuate proopiomelanocortin neuronal (POMC) system. The quantitative image analysis of POMC immunoreactive varicosities in the ME indicates no significant differences between the various rostro-caudal segments. In the main (preinfundibular) portion of the ME, a moderate density of immunoreactive elements was located in the lateral part of the internal zone and throughout the postinfundibular ME. Very few scattered varicosities were observed in the neurohemal (external) zone and in the pituitary stalk. By RIA, alpha-MSH is present in a substantially higher concentration than ACTH and beta-END throughout the ME. Knife cuts between the arcuate nucleus and ME indicate that proopiomelanocortin (POMC) fibers enter the ME in its whole rostro-caudal extent. Thus POMC neurons seem to provide innervation of structures in the internal zone but not in the neurohemal/external/zone where the portal capillary system is located. Moreover, the observation that the density of immunoreactive elements is substantially lower in the pituitary stalk than in the ME, suggests that the majority of immunoreactive fibers in the internal zone are not fibers of passage directed towards the neurohypophysis.

Distribution of the pro-opiomelanocortin derived peptides, adrenocorticotrope hormone, alpha-melanocyte-stimulating hormone and beta-endorphin (ACTH, alpha-MSH, beta-END) in the rat hypothalamus

Rat hypothalamic nuclei were removed and assayed for adrenocorticotropic hormone (ACTH), beta-endorphin (beta-END) and alpha-melanocyte-stimulating hormone (alpha-MSH) content by radioimmunoassay, from the same samples. We also performed immunostaining for these 3 pro-opiomelanocortin (POMC) derived peptides on paraffin embedded serial sections of the hypothalamus. Areas known to project to the external zone of the median eminence receive a dense POMC innervation while those projecting to the posterior pituitary are not innervated. In addition, hypothalamic areas previously suggested to project to medullary autonomic centers are densely innervated. This innervation pattern may provide the morphological basis for the involvement of POMC peptides in neuroendocrine and autonomic functions. The biochemical data raise the possibility that the POMC precursor is processed differently in various brain regions.

Characterization of alpha-melanocyte-stimulating hormone in rat pancreas

Reverse-phase high performance liquid chromatography and radioimmunoassay were used to characterize alpha-melanocyte-stimulating hormone (alpha-MSH)-like peptides in rat pancreas. Relative to synthetic alpha-MSH standards, serial dilutions of pancreas extracts showed parallel and concentration dependent displacement of (125I) alpha-MSH from alpha-MSH antibody. Chromatographic separation revealed immunoreactive material coeluting with synthetic N,O-diacetyl alpha-MSH, which accounted for 78% of total alpha-MSH materials in this tissue. The remainder of immunoreactive alpha-MSH coeluted with synthetic alpha-MSH, desacetyl alpha-MSH, or their methionine sulfoxides. In contrast with anterior pituitary, it appears that biosynthetic processing of alpha-MSH from pro-opiomelanocortin (POMC) may be similar in rat pancreas and pituitary intermediate lobe, since their relative alpha-MSH immunoreactive elution profiles were similar. These findings support the hypothesis of tissue specific regulation of biosynthetic processing of POMC.

Synthesis and biological evaluation of the superagonist [N alpha-chlorotriazinylaminofluorescein-Ser1,Nle4,D-Phe7]-al pha-MSH

The fluorescein-labeled melanotropin [N alpha-chlorotriazinylaminofluorescein-Ser1,Nle4,D-Phe 7]-alpha-MSH, was prepared by solid-phase techniques of peptide synthesis. The biological actions of this analogue were determined in several melanocyte bioassays and were compared with the parent peptide [Nle4,D-Phe7]-alpha-MSH and the native hormone alpha-MSH. The fluorescein compound was a superpotent agonist with approximately 10 times more activity than alpha-MSH in both the frog and the lizard skin bioassays. Murine S91 melanoma cells assayed in vitro (tyrosinase bioassay) were as responsive to the fluorescein analogue as to alpha-MSH. The analogue exhibited ultraprolonged biological activity and the biological activities were unaffected by treatment of the analogue with alpha-chymotrypsin. The fluorescein-labeled melanotropin should prove useful for melanotropin receptor characterization.

Analysis of the antipyretic action of alpha-melanocyte-stimulating hormone in rabbits

alpha-Melanocyte-stimulating hormone (alpha-MSH) or paracetamol was injected into a lateral cerebral ventricle (I.C.V.) of rabbits with elevations in rectal temperature induced by sodium arachidonate (I.C.V.), prostaglandin E2 (I.C.V.) or leucocytic pyrogen (I.V.). alpha-MSH (200 ng) was more effective than paracetamol (0.5 mg) in reducing fever caused by leucocytic pyrogen, but it did not alter hyperthermia induced by sodium arachidonate. In contrast, paracetamol reduced hyperthermic responses to arachidonate by about 70%. Neither alpha-MSH nor paracetamol affected hyperthermic responses to prostaglandin E2. The doses of alpha-MSH and paracetamol used in these experiments did not interfere with thermoregulation in a cold environment (10 degrees C). We conclude (1) that alpha-MSH and paracetamol differ in their central mechanism of antipyresis or (2) that inhibition of arachidonic acid metabolism by paracetamol is not requisite for its antipyretic effect, in which case central release of alpha-MSH may mediate the antipyretic effect of paracetamol.

Anatomy and physiology of the neuroendocrine arcuate nucleus

The arcuate nucleus surrounds the ventral part of the third ventricle and contains densely packed small neurons with 1-3 dendrites. At least fifteen transmitters and neuropeptides have been found in perikarya of arcuate neurons. Each transmitter and neuropeptide have a characteristic distribution. In many cases distributions overlap (for example, dopamine and somatostatin, dopamine and neurotensin, neuropeptide Y and somatostatin) and alpha-MSH and beta-endorphin seem to have identical distributions but there are also distinctive neuronal populations containing only one of the described transmitters or neuropeptides (neuropeptide Y and alpha-MSH). Studies show extensive colocalization of dopamine and neurotensin and sparse colocalization of dopamine and GABA, neuropeptide Y and FMRF-NH2 and neuropeptide Y and somatostatin. Colocalization does not seem to be the rule in the arcuate, however, it is possible that colocalization may vary with the physiological state or sex of the animal. It also should be noted that our techniques may not be sensitive enough. To study efferent projections as a possible organizing principle within the arcuate, retrograde fluorescent tracing was combined with transmitter and neuropeptide immunohistochemistry. Mainly NPY and alpha-MSH neurons were studied and both peptides are present in projections to the preoptic area as well as to the midbrain periaqueductal gray. Some arcuate neurons were found to have collateral axons to both these areas. The arcuate communicates primarily with the pituitary gland, hypothalamus, limbic system, midbrain periaqueductal gray and autonomic nuclei of the brain stem. In this way, the arcuate may be involved in integrating emotional, sensory, vegetative homeostatic and autonomic functions with endocrine functions.

Analysis of the ACTH/beta-End/alpha-MSH-immunoreactive afferent input to the hypothalamic paraventricular nucleus of rat

Immunoreactive fibers and varicosities in the hypothalamic paraventricular nucleus (PVN) were examined by light- and electronmicroscopy, following treatment of brain slices with specific antibodies to adrenocorticotropin (ACTH), beta-endorphin (beta-End) and alpha-melanotropin (alpha-MSH) peptides. In an attempt to provide a more precise, quantitative definition of the densities of immunoreactive elements, sections were analyzed by computer based image-analysis techniques. Fibers and varicosities immunostained with the 3 different antibodies displayed an identical distribution pattern throughout the nucleus suggesting that they are parts of the same, arcuate pro-opiomelanocortin (POMC) neuron system. Although immunoreactive varicosities were found all over the PVN, it was possible to identify a characteristic, density distribution pattern. At the ultrastructural level, immunoreactive presynaptic nerve terminals were observed forming symmetrical synaptic contacts with unlabeled dendrites. The majority of immunoreactive elements were found in the dorsal parvo- and caudal magnocellular subdivisions which give rise to long projections to the lower brainstem. Moderate density of POMC neural elements was observed in the anterior and medial (ventral portion) parvocellular subdivisions which project to the external zone of the median eminence. Only a few, widely scattered immunostained varicosities are found in the medial and lateral magnocellular subdivisions which project to the neurohypophysis. A combined lesion and immunocytochemical approach has shown that the bulk of the afferent neuronal input from arcuate POMC cells enters the PVN from a ventral direction.

Proopiomelanocortin peptide immunocytochemistry in rhesus monkey brain

The immunocytochemical distribution of proopiomelanocortin (POMC) peptides (beta-endorphin, ACTH, alpha-MSH, 16K fragment) was studied in the brain of the rhesus monkey (Macaca mulatta). Some animals were administered colchicine intracerebroventricularly prior to sacrifice to enhance the visualization of perikaryal immunoreactivity. Immunoreactive perikarya are localized to hypothalamic infundibular nucleus, giving rise to several distinct projections. Rostral projections extend through midline diencephalic and preoptic areas, and enter the telencephalon. Along this course, immunoreactive fibers are seen in midline hypothalamic and preoptic nuclei, nucleus of the diagonal band, olfactory tubercle, nucleus accumbens, bed nucleus of stria terminalis, septum, and other limbic structures in telencephalon. Caudal to the anterior commissure, some fibers ascend dorsally to enter the midline thalamus, which they innervate. Lateral projections of the infundibular perikarya course through the medial-basal hypothalamus, dorsal to the optic tracts, and enter the amygdala region where they innervate more medially situated amygdaloid nuclei. Caudal projections of the POMC neurons also extend through midline diencephalon, some coursing along a periventricular path to innervate midline hypothalamic and thalamic nuclei. This projection extends into the mesencephalic substantia grisea centralis and may also contribute to the innervation of more dorsally situated nuclei in the pons and medulla, such as the parabrachial nuclei and nucleus tractus solitarius. Other caudal projections originating in the hypothalamus course through the ventral tegmentum of mesencephalon and pons and may contribute to the innervation of midline raphe and other ventrally situated nuclei in the pons and medulla. The distribution of immunoreactive perikarya and fibers in the brain of rhesus monkey is strikingly similar to that found in the rat brain. However, subtle differences appear to exist in the innervation patterns of particular brain regions.

Neurons of the A1/A2 region in the guinea pig medulla oblongata containing glucagon, glicentin, and dopamine-beta-hydroxylase immunoreactivity

Glucagon- (GLU-IR), glicentin- (GLI-IR) and dopamine-beta-hydroxylase (DBH-IR) immunoreactive neurons were mapped in the medulla oblongata of colchicine pretreated guinea pigs. Numerous GLU-IR and GLI-IR perikarya are located in the area of the nucleus ambiguus, in the adjacent formatio reticularis, and less frequently in the nucleus reticularis lateralis, the nuclei raphe obscurus and commissuralis and the caudal part of the nucleus solitarius. In these nuclei, the coexistence of glicentin and glucagon within the same perikarya is demonstrated. DBH-IR is also found in neurons of the nuclei commissuralis, solitarius and reticularis lateralis (A1/A2 system of Dahlström and Fuxe 1964, 1965). However, a coexistence of GLU/GLI-IR and DBH-IR within the same neuron is not observed.

Novel pharmacology of substance K-binding sites: a third type of tachykinin receptor

The tachykinins are a family of peptides with the carboxyl terminal amino acid sequence Phe-X-Gly-Leu-Met-NH2. Three major mammalian tachykinins have been identified--substance K, neuromedin K, and substance P--but only two tachykinin receptors have been postulated. Three tachykinins were labeled with radioiodinated Bolton-Hunter reagent and their binding characteristics were determined in crude membrane suspensions from several tissues. In cerebral cortex labeled eledoisin exhibited high-affinity binding that was inhibited by tachykinins in a manner indicating a definitive SP-E receptor site. In gastrointestinal smooth muscle and bladder, high-affinity binding of labeled substance P was inhibited in a pattern indicating a definitive SP-P site. In intestinal smooth muscle and bladder, however, labeled substance K and labeled eledoisin were both bound in a pattern indicating a preference for substance K itself. The results suggest the existence of three distinct types of tachykinin receptors: SP-P, SP-E, and SP-K.

Beta-endorphin/ACTH immunocytochemistry in the CNS of the lizard Anolis carolinensis: evidence for a major mesencephalic cell group

The immunocytochemical distribution of beta-endorphin and other proopiomelanocortin (POMC) peptides in the central nervous system of the lizard Anolis carolinensis was determined. Colchicine pretreatment was used to enhance perikaryal immunoreactivity. A major finding of this study is the localization of a previously undetected mesencephalic cell group which exhibits immunoreactivity to beta-endorphin, ACTH, and alpha-MSH. The perikarya of these neurons are large, bipolar, and situated in the mesencephalic tegmental area. They appear to project to the mesencephalic central gray and other brainstem structures. In contrast, the immunoreactive parvicellular perikarya of the medial-basal hypothalamus, corresponding to the POMC perikarya of the rodent arcuate nucleus, exhibit major rostral projections to various telencephalic and diencephalic structures. The exact extent of fiber projections and innervation patterns arising from either of these two groups is not clear at this time and will require further analyses. Scattered fiber immunoreactivity was also seen in the medial cerebral cortex and the striatal complex, regions which apparently are not innervated by beta-endorphin fibers in the rodent brain. Also, no immunoreactivity was seen to an antiserum to the 16K peptide of POMC. Other similarities and differences in the brain distribution of POMC in reptiles and mammals are discussed.

Differential in vitro metabolism of beta-endorphin in schizophrenia

Biologically active peptide fragments derived from the proteolytic cleavage of beta-endorphin (beta E) have been shown to be present in the brain. Based on clinical results using some of these fragments in neuropsychiatric disease studies we investigated the in vitro metabolism of beta E by twice-washed membrane homogenates of postmortem putamen from sex and age matched controls versus subjects with a diagnosis of schizophrenia. The present study demonstrates that frozen (-80 degrees C) postmortem human tissues are viable for these studies and that metabolism in control tissue proceeds similarly to fresh tissues. Furthermore, a significant increase in the formation of the putative neuroleptic-like peptide fragment des-enkephalin-gamma-endorphin in postmortem schizophrenic putamen versus controls was shown. A significant decrease in the formation of beta E was also reported. These data suggest that an approach using postmortem human brain is possible in studying beta-endorphin catabolism and is therefore applicable to other neuropeptide systems.

Characterization of in vitro proteolytic processing of beta-endorphin by reversed-phase HPLC

In vitro, central and peripheral proteolytic processing of beta-endorphin by membrane-bound enzymes results in the formation of specific active fragments that have been recently shown to function in behavior, intestinal motility and in the central control of urinary bladder activity. A high resolution, reversed phase high performance liquid chromatography system capable of separating 28 beta-endorphin related fragments simultaneously was used to study the time-course processing of beta-endorphin by membrane associated peptidases in the brain and regions of the small intestine. The hypothesis we tested was that a homeostatic balance between alpha- and gamma-type endorphins exists in these tissues. The results of the study show that the rate and quantity of fragments produced between the mucosa and nerve-muscle regions of the small intestine are significantly different. Metabolic rates, pattern, and the ratio of alpha/gamma-type endorphins in the brain were very similar to the nerve-muscle region of the small intestine. This suggests that beta-endorphin processing to active fragments is occurring at the nerves of the small intestine and that a specific and similar balance of alpha/gamma-type endorphin exists in the brain and gastrointestinal system at neutral pH.

Relative stability of alpha-melanotropin and related analogues to rat brain homogenates

alpha-Melanotropin (alpha-MSH) retains less than 1% of its original activity after a 60 min incubation with 10% rat brain homogenate. [Nle4,D-Phe7]-alpha-MSH is nonbiodegradable in rat serum (240 min incubation) and still maintains 10% of its original activity in 10% rat brain homogenate (240 min incubation). The related fragment analogue, Ac-[Nle4,D-Phe7]-alpha-MSH4-10-NH2, retains 50% of its activity after a 240 min incubation in rat brain homogenate, whereas Ac-[Nle4,D-Phe7]-alpha-MSH4-11-NH2 is totally resistant to inactivation by rat brain homogenate. Both [Nle4,D-Phe7]-fragments are resistant to degradation by rat serum, but [Nle4]-alpha-MSH, Ac-[Nle4]-alpha-MSH4-10-NH2 and Ac-[Nle4]-alpha-MSH4-11-NH2 are rapidly inactivated under both conditions. The cyclic melanotropin, [Cys4,Cys10]-alpha-MSH, is inactivated in rat brain homogenate as is the shorter Ac-[Cys4,Cys10]-alpha-MSH4-10-NH2 analogue, but neither cyclic melanotropin is inactivated upon incubation in serum from rats. Ac-[Cys4,D-Phe7,Cys10]-alpha-MSH4-10-NH2 is resistant to inactivation by either rat serum or a brain homogenate. Some of these melanotropin analogues may provide useful probes for the localization and characterization of putative melanotropin receptors in both the central nervous system and peripheral tissues.

Structural and conformational modifications of alpha-MSH/ACTH4-10 provide melanotropin analogues with highly potent behavioral activities

Previous studies have identified the (4-10) heptapeptide sequence as the central core of alpha-MSH/ACTH peptides required for mediation of important biological activities. In the present study, the structure-activity relationships of Nle4-substituted and Cys4,Cys10-bridged cyclic alpha-MSH analogues, which were previously shown to exhibit a wide range of melanotropic potencies from weak agonism to super potency, were examined for grooming behavioral activity in the rat following intracerebroventricular injections. The results showed that stepwise C-terminal elongation of the linear Nle4-substituted Ac-alpha-MSH4-10-NH2 increased grooming potencies of the peptides in a manner similar to their actions on melanocytes. The most interesting finding was the observation that cyclization of the inactive linear "central (4-10) core" of alpha-MSH (Ac-alpha-MSH4-10) to form Ac-[Cys4,Cys10]-alpha-MSH4-10-NH2 resulted in a super potent agonist in the grooming assay. However, while cyclization of the (4-10) heptapeptide produced potent agonists on grooming behavior, the structure-activity relationships were different than the frog skin bioassay. These findings support the hypothesis that appropriate structural and confirmational modifications of alpha-MSH-related peptides can produce profound effects on the bioactivities of the peptides, and suggest that different structural-conformational requirements exist for alpha-MSH interactions with its various receptors.

Saline drinking and naloxone: Lightcycle dependent effects on social behaviour in male mice

Male mice (TO strain) were observed in the resident-intruder test and several behaviours monitored. Treatments were: isotonic saline drinking ad lib for 48 hours before testing (SAL), IP injections of 1 mg/kg naloxone 30 minutes before testing (NLX) or both treatments combined (NLX + SAL). The same sequence of tests were carried out both in the light and the dark phase of the 24-hour light cycle. The single treatments (SAL and NLX) both increased fighting (SAL, p less than 0.02) in the light phase. The combined treatment (NLX + SAL), which reduced behavioural activity overall, caused a marked increase in the proportion of behaviour time spent on aggression (p less than 0.002). These effects were either reversed (significant reductions in aggression with SAL and NLX, p less than 0.05) or cancelled (minor reduction, NLX + SAL) in the dark phase. Partner body sniffing showed a trend towards lower levels following treatments in the light, and higher levels in the dark. No other behaviour changed systematically with treatments. Plasma sodium levels were monitored: there was a trend of treatment group mean sodium levels changing in proportion to the aggressogenic effect of the treatment, but it was not confirmed by correlation tests on the plasma sodium and aggression levels of individuals. The data are discussed in terms of a possible interaction between opioid receptors and physiological sodium chloride loads.

Bilateral alpha-melanocyte stimulating hormonergic fiber system from zona incerta to cerebral cortex: combined retrograde axonal transport and immunohistochemical study

We employed a highly sensitive combination method of retrograde tracing and immunohistochemistry to identify an alpha-melanocyte-stimulating hormone (alpha-MSH)-containing fiber pathway from zona incerta to cerebral cortex. Biotin-horseradish peroxidase injected into the parietal cortex of the rat labeled a number of neurons in the zona incerta bilaterally, and simultaneous staining with an alpha-MSH antiserum revealed that a part of these neurons are alpha-MSHergic.

Interactions between cardiovascular and pain regulatory systems

A review of pharmacological, neuroanatomical, electrophysiological, and behavioral data indicates that systems controlling cardiovascular function are closely coupled to systems modulating the perception of pain. This view is directly supported by experiments from our laboratory showing that activation of either the cardiopulmonary baroreceptor reflex arc or the sinoaortic baroreceptor reflex arc induces antinociception. The outcomes of studies using pharmacological treatments, peripheral nerve stimulation, peripheral nerve resection, and CNS lesions are also presented as a preliminary means of characterizing cardiovascular input to pain regulatory systems. The network formed by these systems is proposed to participate in the elaboration of adaptive responses to physical and psychological stressors at various levels of the neuroaxis, and possibly to participate in "diseases of adaptation." In particular, the present analysis suggests that the inhibition of pain brought about by elevations in either arterial or venous blood pressure may provide a form of psychophysiological relief under situations of stress and contribute to the development of essential hypertension in humans.

Regional heterogeneity in the ratio of alpha-MSH: beta-endorphin in rat brain

The molar ratio of alpha-MSH: beta-endorphin varies markedly among discrete microdissected regions of rat brain ranging from 0.57 in the median eminence to 2.74 in the lateral septum. This finding demonstrates that alpha-MSH and beta-endorphin (beta-END) are not uniformly distributed in a 1:1 molar ratio in rat brain as one might predict based on the consideration that the two peptides are synthesized in equimolar amounts as part of a common precursor molecule, pro-opiomelanocortin. The data indicate instead that the concentrations of alpha-MSH and beta-END, the two predominant peptides expressed by opiomelantropinergic neurons, are independently regulated in rat brain. The heterogeneity of alpha-MSH: beta-END ratios suggests that the regulation of alpha-MSH and beta-END is regionally specific and may impart functional selectivity to the multisecretory opiomelanotropinergic neuronal system.

Melanotropin bioassays: in vitro and in vivo comparisons

A reflectance method was utilized to compare the in vitro responses in three species of frogs (Rana pipiens, R. berlandieri forrei, and R. catesbeiana) and a lizard (Anolis carolinensis) to alpha- and beta-melanotropins (alpha- and beta p-MSH). The integumental chromatic response of the three ranid species was identical, in that alpha-MSH was about 2 times more potent than beta p-MSH. The melanotropins were equipotent in the lizard skin bioassay. A remarkable feature of the Anolis skin assay is that skins from this lizard can be utilized repeatedly many times in one day with an extremely high degree of precision. The reflectance method was also used to determine the in vivo potencies of alpha-MSH and beta p-MSH in the frog, R. pipiens. Surprisingly, the melanotropins were more active in the in vivo assay than in the in vitro bioassay. The darkening response of the frogs to alpha-MSH was reversed by 6 hr, but the response to beta p-MSH persisted for more than 8 hr. When alpha-MSH was incubated in frog serum, the melanotropic activity was almost totally abolished by 30 min, whereas the melanotropic activity of beta p-MSH was evident much longer (4 hr) in the presence of the serum. In light of the observation that the melanotropic activity of alpha-MSH is rapidly lost by incubation in frog serum, it is unclear why the hormone was more active as measured in vivo and why the darkening response in vivo persisted so long.

Quantification of the permeability of the blood-CSF barrier to alpha-MSH in the rat

The ability of alpha-MSH to cross the blood-CSF barrier of the rat was assessed by measurement of the rate of appearance of immunoreactive alpha-MSH in a cerebrospinal fluid (CSF) perfusate following intravenous injection of peptide. Comparisons were made with the rate of appearance of a simultaneously administered dose of 14C-inulin which is poorly permeable at the blood-CSF barrier. Concentrations of drugs measured in plasma were fitted to two-compartment pharmacokinetic models, and those measured in the CSF perfusate to one-compartment open systems receiving an input from the plasma compartment. The rate constant for entry of alpha-MSH into CSF was 0.00087 min-1, which was not significantly different from that for inulin of 0.00055 min-1. As alpha-MSH penetrated into CSF at a rate comparable to inulin, it was concluded that the limited entry of peptide was by aqueous diffusion along with other water-soluble macromolecules.

ACTH1-24 effects on d-amphetamine self-administration and the dynamics of brain dopamine in rats

Experiments aimed at determining the neural basis of reward have previously focused on the role of neurotransmitters and have only recently begun to investigate the role of peptides. The present experiment investigated the effect of ACTH1-24 on d-amphetamine self-administration in rats. Animals were trained daily (8 hour sessions) to press a lever which activated a system that administered 0.125 mg/kg of intravenous amphetamine. After achievement of a stable self-injection frequency, subjects were injected SC with 10, 20 or 40 micrograms/80 microliters ACTH1-24 immediately prior to placement in the apparatus. The 20 micrograms and 40 micrograms doses of the peptide fragment induced a statistically significant attenuation of d-amphetamine self-injection which lasted for 2 days. Control rates of responding were achieved by 5 to 10 days after the peptide treatment. An experiment was conducted to evaluate possible neuromodulatory effects of the peptide fragment. Twenty-four hr after ACTH1-24, HVA was elevated in the caudate. When both apomorphine and ACTH1-24 were administered, the combination lowered HVA in the caudate to a greater degree than apomorphine alone. The peptide fragment, when combined with haloperidol, attenuated the haloperidol-induced increases of DOPAC and HVA in both the caudate and nucleus accumbens. It was tentatively concluded that the neuromodulatory action of ACTH1-24 on dopaminergic neurons may result in an increase in the rewarding quality of d-amphetamine, thus rendering control level self-infusions superfluous.(ABSTRACT TRUNCATED AT 250 WORDS)

The distribution of alpha-melanocyte stimulating hormone (alpha-MSH) in the central nervous system of the rat: an immunohistochemical study. II. Lower brain stem

The distribution of immunoreactive alpha-melanocyte stimulating hormone (alpha-MSHI) in the rat lower brain stem was examined by indirect immunofluorescence or peroxidase- anti-peroxidase immunohistochemical method using an antiserum against synthetic alpha-MSH. The results confirmed the presence of alpha-MSHI fibers in the midbrain central gray matter and parabrachial area, and demonstrated a much more extensive distribution of these fibers in various parts of the lower brain stem areas previously thought not contain alpha-MSHI fibers. In addition, the commissural nucleus was identified as a new alpha-MSHI neurons-containing site. No alpha-MSHI neurons were seen in other regions of the rat lower brain stem.

Synthesis of a cyclic melanotropic peptide exhibiting both melanin-concentrating and -dispersing activities

A putative melanin-concentrating hormone was synthesized. This peptide, H-Asp-Thr-Met-Arg-Cys-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val-OH , stimulates melanin granule aggregation within teleost melanocytes at nanomolar concentrations as does the natural purified teleost pituitary preparation. In addition, this peptide stimulates melanin granule dispersion within melanocytes of frogs and lizards. The peptide has about one six-hundredth of the activity of alpha-melanocyte-stimulating hormone on frog and lizard melanocytes and is a full agonist.

Immunoreactive-beta-endorphin and LHRH levels in the brains of aged male rats with impaired sex behavior

Levels of immunoreactive beta-endorphin and luteinizing hormone releasing hormone (LHRH) were measured in brain tissue of aged male Long-Evans rats. The animals were tested for sex behavior twice in one week at bimonthly intervals between the 7th and 27th month of life and were sacrificed along with a group of young (5-month old) sexually active rats. Thirty-one of the 89 rats which began the study remained healthy and tumor-free. By month 27, 21 of these had completely ceased to mate and 10 continued to show adequate sexual behavior. Diminished levels of beta-endorphin-like immunoreactivity were measured in the hypothalami and hindbrain of the old animals grouped together as compared to young animals and this reduction was shown to be significantly greater in hypothalamic tissue from the behaviorally inactive subgroup. Hypothalamic LHRH levels were not significantly altered by age in these animals. However, a marked reduction of LHRH content in the septal and midbrain regions of the aged-behaviorally inactive subgroup was evident when compared with the behaviorally active group. The data suggest that altered function of beta-endorphin and LHRH neurons of the aged brain may be involved in the behavioral deterioration observed in aged animals.

Comparative biological activities of potent active-site analogues of alpha-melanotropin. Effect of tyrosine substitution at position-4

We have prepared several alpha-melanotropin (alpha-MSH) analogues with tyrosine substituted for methionine at the 4-position and determined their melanotropic activities on the frog (Rana pipiens), lizard (Anolis carolinensis) and S-91 (Cloudman) mouse melanoma adenylate cyclase bioassays. The potencies of Ac-[Tyr4]-alpha-MSH4-10-NH2 and Ac-[Tyr4]-alpha-MSH4-11-NH2 were compared with alpha-MSH and with their corresponding methionine and norleucine substituted analogues. The Tyr-4 analogues were found to be less active than the Nle-4 analogues on both the frog and lizard assays. Ac-[Tyr4]-alpha-MSH4-10-NH2 was found to be less active than Ac-[Tyr4]-alpha-MSH4-11-NH2 on the lizard bioassay, but more active than the longer fragment on the frog skin assay. Ac-[Tyr4]-alpha-MSH4-10-NH2 exhibited extremely prolonged biological activity on frog skin, but not on lizard skin, while the melanotropic activity of Ac-[Tyr4]-alpha-MSH4-11-NH2 was rapidly reversed on both assay systems. The increased potency of Ac-[Tyr4]-alpha-MSH4-10-NH2 over Ac-[Tyr4]-alpha-MSH4-11-NH2 on frog melanocytes may be related to the fact that the shorter 4-10 analogue exhibits prolonged biological activity. Interestingly, it was found that both Tyr-4 analogues were partial agonists on the mouse melanoma adenylate cyclase bioassay, and stimulated the enzyme to only about 50% of the maximal activity of alpha-MSH. We reported previously that replacement of L-Phe-7 by its D-enantiomer in [Nle4]-alpha-MSH and its Nle-4 containing analogues resulted in peptides with increased potency and in some instances prolonged activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Synthesis of tritium labeled Ac-[Nle4, D-Phe7]-alpha-MSH4-11-NH2: a superpotent melanotropin with prolonged biological activity

Ac-[Nle4, D-Phe7]-alpha-MSH4-11-NH2 an octapeptide, is a melanotropin analogue (Ac-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-NH2), which is a superpotent agonist of frog and lizard skin melanocytes and mouse S 91 (Cloudman) melanoma cells. This melanotropin possesses ultraprolonged activity on melanocytes, both in vitro and in vivo, and the peptide is resistant to inactivation by serum enzymes. The tritium-labeled congener was prepared by direct incorporation of [3H]-labeled norleucine into the peptide. The melanotropic activity of the labeled peptide is identical to the unlabeled analogue. This labeled peptide should be useful for studies on the localization and characterization of melanotropin receptors.

Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents

Using [3H]para-aminoclonidine, alpha 2 adrenergic binding sites have been mapped in the rat and human CNS using in vitro labeling autoradiographic techniques. In both the rat and human thoracic spinal cord, high densities of alpha 2 binding sites were associated with the substantia gelatinosa and the intermediolateral cell column. In the rat medulla, high binding site density was observed in the medial nucleus of the solitary tract, dorsal motor nucleus of the vagus, raphe pallidus and the substantia gelatinosa of the trigeminal nucleus, while lower levels of specific binding were found in the lateral and ventrolateral medulla. In the human, a similar distribution was observed. However, significantly lower levels of specific binding were seen in the medial nts as opposed to the dmv. In the rat, high levels of specific binding were seen at pontine and midbrain levels in the locus coeruleus, parabrachial nucleus and periaqueductal gray. In the forebrain, several hypothalmic and limbic regions, including the paraventricular and arcuate nuclei of the hypothalamus, the central, medial and basal nuclei of the amygdala, lateral septum and bed nucleus of the stria terminalis and pyriform, entorhinal and insular cortex were labeled. Each of these regions are involved in either modulating autonomic functions directly or integrating somatosensory and/or affective function with autonomic mechanisms. Further, these regions are interrelated by reciprocal connections, and neurons that utilize noradrenaline or adrenaline as their neurotransmitter form a vital part of these connections. Thus, these functional, anatomical and neurochemical correlates of the alpha 2 binding site distribution establish a neurological basis for the complex pharmacological effects of centrally acting alpha 2 agonists.

Lack of correlation between amniotic fluid and maternal plasma contents of beta-endorphin, beta-lipotropin, and adrenocorticotropic hormone in normal and pathologic pregnancies

Reported are the concentrations of beta-endorphin, beta-lipotropin, and adrenocorticotropic hormone (ACTH) in the amniotic fluid and plasma of 40 healthy pregnant women at different stages of gestation. Moreover, the amniotic fluid levels of the three peptides were evaluated in 20 other pregnant women affected by different pathologic conditions (Cooley's disease, gestosis, diabetes, placental insufficiency, etc.). A silicic acid extraction procedure was performed on the samples. Each extract was subjected to Sephadex G-75 column chromatography, and the two fractions corresponding to beta-lipotropin and beta-endorphin were collected, freeze-dried, and assayed by two specific radioimmunoassays. Levels of ACTH were measured by radioimmunoassay directly on the extracts. Levels of beta-endorphin in amniotic fluid showed the highest values in the first trimester (173 +/- 30 fmol/ml, mean +/- SEM) but were significantly decreased in the second (75.2 +/- 14) and third trimesters (14.3 +/- 1.8). An inverse trend characterized plasma levels of beta-endorphin, which showed a progressive increase from the first trimester to term (10.4 +/- 11.1). Amniotic fluid levels of beta-lipotropin remained stable during the first (48.6 +/- 6.3) and second (54.6 +/- 11.1) trimesters, but decreased significantly in the third trimester (17.9 +/- 2.3). The plasma concentrations of beta-lipotropin showed the highest levels in the first trimester (10.9 +/- 0.9), and decreased significantly at term (8.9 +/- 1.3). Last, amniotic fluid levels of ACTH decreased from 55.3 +/- 4.75 fmol/ml in the first trimester to 12.5 +/- 1.16 in the second trimester, and rose again in the third trimester to 34.4 +/- 6.6 fmol/ml. Plasma levels of ACTH were characterized in the first two trimesters by values twice those recorded for nonpregnant women, and decreased at term to 8.9 +/- 1.4 fmol/ml. In the pregnant patients with fetuses affected by Cooley's disease (second trimester) and in those with edema-proteinuria-hypertension (EPH) gestosis (third trimester), amniotic fluid levels of beta-endorphin, beta-lipotropin, and ACTH were in the same range as those in healthy pregnant women.

Corticosterone decreases the efficacy of adrenaline to affect passive avoidance retention of adrenalectomized rats

Short-term (48h) adrenalectomy (ADX) resulted in a deficit in the retention of a passive avoidance response. An inverted U-shaped dose-response relationship was found following immediate post-learning administration of adrenaline (A). A in a dose range of 0.005 - 5 micrograms/kg s.c. facilitated later retention. While corticosterone (CS) replacement alone had no effect, pretreatment with CS (300 micrograms/kg) was followed by a shift in the dose-response curve of A in ADX rats. Ten thousand times higher doses of A were required to improve retention behavior. Administration of the potent synthetic glucocorticoid dexamethasone failed to affect the responsiveness to A. It is concluded that corticosterone decreases the efficacy by which adrenaline affects later retention behavior of ADX rats. The specificity of corticosterone in this interaction suggests the involvement of the corticosterone receptor system which has its predominant localization in hippocampal neurons.

Strategies for studying opioid peptide regulation at the gene, message and protein levels

Three opioid peptide precursors have been isolated and characterized in endocrine and nervous tissue: pro-opiomelanocortin, pro-enkephalin, and pro-dynorphin. Since each of those opioid peptide systems have been extensively characterized both biochemically and anatomically, this review will focus on strategies for studying the regulation of these systems at the levels of gene transcription, message translation, post-translational processing, secretion, and target cell receptor interaction.

Enzymological studies of melanotropins

The relative stability of natural melanotropins and related synthetic analogues to serum and purified proteolytic enzymes was studied. Both alpha- and beta-MSH were rapidly inactivated by frog serum, but much more slowly by rat serum. beta-MSH was more stable than alpha-MSH to serum inactivation. Both alpha- and beta-MSH were rapidly inactivated by alpha-chymotrypsin and trypsin. The synthetic analogues, [Nle4, D-Phe7]-alpha-MSH and [Cys4, Cys10]-alpha-MSH, were totally resistant to inactivation by frog and rat serum enzymes. [Nle4, D-Phe7]-alpha-MSH was resistant to inactivation by alpha-chymotrypsin and trypsin, whereas [Cys4, Cys10]-alpha-MSH was partially resistant to these enzymes under similar conditions. Melanotropin analogues resistant to inactivation by serum enzymes may prove useful in a variety of physiological studies wherein natural melanotropins would be rapidly inactivated.

Further characterization of the major forms of reptile beta-endorphin

Biosynthetically labeled reptile intermediate pituitary beta-endorphin-sized material was fractionated by SP-Sephadex ion exchange chromatography into two major opiate-active forms which eluted at 0.28 M NaCl and 0.32 M NaCl, respectively; the 0.32 M form of reptile beta-endorphin (mw = 3500), serves as the precursor for the 0.28 M form of reptile beta-endorphin (mw = 3200), (Dores and Surprenant, 1983). Analysis of tryptic digests of these reptile beta-endorphins by paper electrophoresis at pH 3.5 and gel filtration on a Sephadex G-15 column indicated that there are two tyrosine residues, two arginine residues and one methionine residue in reptile beta-endorphin. Furthermore, the NH2-terminal tryptic peptide of both reptile beta-endorphins is approximately nine amino acids in size and contains tyrosine, methionine and arginine. Analyses of chymotryptic/protease digests of the [3H]tyrosine-labeled NH2-terminal tryptic peptide analyzed by descending paper chromatography revealed that the NH2-terminal tyrosine of reptile beta-endorphin is not alpha-N-acetylated. A second tyrosine-containing tryptic peptide was detected in the COOH-terminal region of reptile beta-endorphin; however this tryptic peptide differs in the two forms of reptile beta-endorphin in terms of size and net charge at pH 3.5. These differences account for the apparent molecular weight differences and distinct ion exchange properties of the 0.28 M and 0.32 M forms of reptile beta-endorphin. Thus in the reptile intermediate pituitary the principal post-translational mechanism for modifying beta-endorphin is COOH-terminal proteolytic cleavage.

Biosynthesis of multiple forms of beta-endorphin in the reptile intermediate pituitary

Fractionation of the beta-endorphin-sized material from freshly dissected reptile intermediate pituitaries by ion exchange chromatography on sulfopropyl Sephadex (SP) revealed at least three distinct forms of immunoreactive beta-endorphin. These forms eluted at 0.25 M NaCl, 0.28 M NaCl, and 0.32 M NaCl and represent respectively, 6%, 65% and 29% of the total immunoreactivity. Only the 0.28 M NaCl peak and the 0.32 M NaCl peak exhibited naloxone reversible opiate bioactivity when tested in the isolated guinea pig ileum bioassay system; taking into account the molar amount of immunoreactive peptides the 0.32 M NaCl peak was 6 fold more potent than the 0.28 M NaCl peak. Intermediate pituitaries in culture were incubated with either [3H]tyrosine, [3H]arginine, or [35S]methionine for periods up to 24 hours and beta-endorphin-sized peptides were prepared by immunoprecipitation and gel filtration. Fractionation of the labeled beta-endorphin-sized peptides by ion exchange chromatography yielded profiles nearly identical to the immunoassay analyses of freshly dissected tissue. Further analysis of the major labeled forms of reptile beta-endorphin by chromatography on Sephadex G-50 equilibrated in 6 M guanidine HCl indicated that the 0.32 M NaCl peak had an apparent molecular weight of 3500 +/- 100 and the 0.28 M NaCl peak had an apparent molecular weight of 3200 +/- 100. Furthermore, pulse/chase experiments showed that the 0.32 M NaCl peak was the precursor for the 0.28 M NaCl peak. These results coupled with the relative opiate bioactivities of the major argue that the principal post-translational modification of reptile beta-endorphin is COOH-terminal proteolytic cleavage.

Effect of dopaminergic drugs on hypothalamic and pituitary immunoreactive beta-endorphin concentrations in the rat

Beta-endorphin concentrations have been evaluated in the hypothalamus, pituitary lobes and plasma after 1-and 3-week treatment with 2-Br-alpha-ergocriptine or lisuride, two potent dopaminergic drugs. Hypothalamic beta-endorphin concentrations were significantly decreased after the administration of the dopaminergic agents for 1 or 3 weeks. Similarly, beta-endorphin concentrations decreased in the neurointermediate lobe and plasma. After gel chromatography, it appeared that in the anterior pituitary, beta-lipotropin concentrations were unchanged or lightly increased concomitantly with a decrease of beta-endorphin. Our data indicate that, both in the hypothalamus and the neurointermediate pituitary lobe, beta-endorphin is under an inhibitory dopaminergic tone. The latter may also play a role in inhibiting beta-endorphin cleavage from beta-lipotropin in the anterior pituitary.

Neurofilaments contain alpha-melanocyte-stimulating hormone (alpha-MSH)-like immunoreactivity

An antiserum to alpha-melanocyte-stimulating hormone (alpha-MSH) was found to contain antibodies to at least two types of determinants on the alpha-MSH peptide: one is present only on the free peptide, the other is shared with neurofilaments. Immunoblots from mouse brain showed the neurofilament crossreactivity to be located on proteins in the Mr 140,000 range. The neurofilament-crossreactive portion of the antiserum could be selectively absorbed out with a cytoskeletal preparation, which abolished all affinity of the antiserum to the retina but did not affect the labeling pattern in the pituitary. Absorptions with desacetyl-alpha-MSH and corticotropin seemed to indicate that the determinant shared with neurofilaments is not located at either end of the alpha-MSH peptide, but somewhere in between. The immunohistochemical labeling of the retina with the alpha-MSH antiserum was compared to the labeling with monoclonal antibodies against Mr 200,000 neurofilaments. In the adult retina the alpha-MSH-like immunoreactivity was found to be slightly more widespread; most consistently it was detectable in cell bodies of large ganglion cells, whereas the heavy neurofilament subunit was absent from somata and proximal axons of these cells. In the developing mouse brain, expression of the heavy subunit was found to lag 2-3 wk behind expression of the Mr 140,000 proteins. This confirms previous reports of a more restricted distribution and late expression of high molecular weight neurofilaments as compared to the lower subunits.